Loading...
XNYS
ENOV
Market cap1.45bUSD
Jul 09, Last price  
25.22USD
1D
6.73%
1Q
3.28%
Jan 2017
-59.22%
IPO
-28.52%
Name

Enovis Corp

Chart & Performance

D1W1MN
XNYS:ENOV chart
P/E
P/S
0.65
EPS
Div Yield, %
Shrs. gr., 5y
4.17%
Rev. gr., 5y
14.94%
Revenues
2.25b
+6.66%
393,604,000506,305,000604,854,000525,024,000541,987,000693,392,0003,913,856,0004,207,209,0004,624,476,0003,967,053,0003,647,047,0003,300,184,0003,666,812,0003,327,458,0001,120,700,0001,426,188,0001,563,101,0001,707,197,0002,107,623,0002,248,049,000
Net income
-1.18b
L+43.48%
94,00064,882,000-571,00021,722,00016,215,0004,555,000-64,402,000178,628,000392,098,000167,739,000128,111,000151,090,000140,196,000-527,646,00042,625,00071,657,000-13,292,000-33,261,000-825,494,000-1,184,440,000
CFO
217m
+91.44%
-17,355,00074,483,000-31,513,00038,286,00061,965,00057,153,000164,299,000362,169,000385,758,000303,813,000246,974,000218,770,000226,367,000130,948,000301,935,000356,099,000-55,861,000134,988,000113,504,000217,293,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Colfax Corporation operates as a global, diversified technology enterprise. Its operations are divided into two primary divisions: Fabrication Technology and Medical Technology. The Fabrication Technology segment is responsible for the creation, refinement, production, and supply of various consumable products and associated equipment. This includes items for cutting, joining, and automated welding, alongside gas control apparatus. Their offerings encompass welding consumables like electrodes, cored and solid wires, and fluxes, crafted from a range of specialized materials. Additionally, they provide cutting consumables such as electrodes, nozzles, shields, and tips. Products from this segment reach markets including infrastructure, wind energy, marine/life sciences, pipelines, mobile/off-highway machinery, and the oil, gas, and mining sectors. Sales are conducted via independent distributors and direct channels, primarily under the ESAB brand. The Medical Technology segment focuses on developing, manufacturing, and distributing medical devices. These products are utilized by a broad spectrum of healthcare professionals, including orthopedic specialists, spine surgeons, general practitioners, pain management experts, physical therapists, podiatrists, chiropractors, and athletic trainers, to address patients' musculoskeletal conditions. These conditions often stem from degenerative diseases, congenital deformities, traumatic injuries, or sports-related incidents. The product portfolio features rigid and soft orthopedic bracing solutions, hot and cold therapy items, bone growth stimulators, vascular therapy systems with compression garments, therapeutic footwear and inserts, electrical stimulators for pain relief, and various physical therapy tools. Furthermore, this segment offers a comprehensive array of reconstructive joint products for hips, knees, shoulders, elbows, feet, ankles, and fingers. Distribution channels include independent distributors (such as healthcare professionals, consumer retail stores, and pharmacies) as well as direct sales, with the DJO brand being prominent. Colfax Corporation was established in 1860 and maintains its headquarters in Wilmington, Delaware.
IPO date
May 08, 2008
Employees
16,200
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT